Lab
Catholic Health Initiatives-Iowa Corp
Catholic Health Initiatives-Iowa Corp was paid $8.00M by Medicaid between Jan 2018 and Dec 2024, across 183 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 27% of everything it billed.
33Billing provider infoCATHOLIC HEALTH INITIATIVES-IOWA CORP
DES MOINES, IA 50314
DES MOINES, IA 50314
33aNPI1104982743assigned 12/28/2006
33bProvider typeClinical Medical Laboratory
28Total paid$8.00M
24GClaims457,489
24DCodes billed183
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Iowa
Rank by total paid#3 of 35
Median peer was paid$42K
This provider vs. median192×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 112,736 | $1.38M | |
| 2019 | 61,896 | $834K | |
| 2020 | 52,071 | $1.44M | |
| 2021 | 75,083 | $2.02M | |
| 2022 | 63,340 | $1.28M | |
| 2023 | 47,183 | $618K | |
| 2024incomplete | 45,180 | $426K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 27% | 26,854 | 24,856 | $2.17M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 5.3% | 12,380 | 12,006 | $421K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 5.1% | 3,020 | 2,962 | $412K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 5.0% | 17,107 | 16,290 | $403K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.3% | 24,249 | 23,203 | $346K |
| 80053 | Comprehensive metabolic panel | 3.6% | 30,272 | 28,598 | $288K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.6% | 8,148 | 7,769 | $286K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.6% | 8,118 | 7,738 | $285K |
| 80061 | Lipid panel | 2.8% | 18,730 | 18,096 | $225K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.1% | 5,284 | 4,906 | $172K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.8% | 7,226 | 6,667 | $145K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.6% | 5,172 | 4,907 | $125K |
171 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.6% | 4,661 | $124K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 1,299 | $119K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.5% | 15,816 | $118K |
| 84439 | 1.3% | 13,653 | $108K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 14,192 | $92K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 2,862 | $86K |
| 86780 | 1.0% | 6,592 | $81K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 11,617 | $80K |
| 86803 | <1% | 6,395 | $79K | |
| 82607 | <1% | 4,869 | $68K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,859 | $63K |
| 83655 | <1% | 4,727 | $60K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 2,471 | $58K |
| 80074 | <1% | 1,457 | $52K | |
| 80050 | General health panel | <1% | 960 | $47K |
| 87070 | <1% | 5,356 | $47K | |
| 86762 | <1% | 3,651 | $46K | |
| 87186 | <1% | 5,222 | $44K | |
| 82728 | <1% | 3,773 | $44K | |
| 87340 | <1% | 4,847 | $43K | |
| 86480 | <1% | 746 | $42K | |
| 83970 | <1% | 1,242 | $42K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 811 | $41K |
| 83516 | <1% | 2,075 | $36K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,454 | $35K |
| 85027 | <1% | 6,429 | $34K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,165 | $33K |
| 83550 | <1% | 4,113 | $30K | |
| 87081 | <1% | 4,194 | $30K | |
| 86850 | <1% | 4,082 | $30K | |
| 82746 | <1% | 2,222 | $30K | |
| 84702 | <1% | 2,366 | $28K | |
| 87077 | <1% | 3,587 | $28K | |
| 86038 | <1% | 2,255 | $26K | |
| 83735 | <1% | 4,161 | $24K | |
| 83540 | <1% | 4,360 | $24K | |
| 82570 | <1% | 5,123 | $24K | |
| 80076 | <1% | 2,947 | $23K | |
| 84153 | <1% | 1,322 | $23K | |
| 86003 | <1% | 1,558 | $22K | |
| 82784 | <1% | 1,967 | $21K | |
| 87529 | <1% | 441 | $20K | |
| 84403 | <1% | 809 | $20K | |
| 86255 | <1% | 1,155 | $20K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 56 | $19K |
| 86140 | <1% | 3,753 | $18K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 586 | $18K |
| 82043 | <1% | 3,328 | $18K | |
| 87205 | <1% | 3,970 | $17K | |
| 86481 | <1% | 188 | $15K | |
| 87899 | <1% | 927 | $14K | |
| 84481 | <1% | 868 | $14K | |
| 87088 | <1% | 1,906 | $14K | |
| 83690 | <1% | 2,103 | $14K | |
| 84146 | <1% | 697 | $14K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 33 | $13K |
| 83001 | <1% | 673 | $12K | |
| 85610 | <1% | 4,061 | $12K | |
| 84460 | <1% | 4,417 | $11K | |
| 87493 | <1% | 318 | $11K | |
| 86900 | <1% | 3,875 | $11K | |
| 86901 | <1% | 3,796 | $10K | |
| 87480 | <1% | 536 | $9K | |
| 87660 | <1% | 532 | $9K | |
| 87510 | <1% | 524 | $9K | |
| 81001 | <1% | 3,385 | $9K | |
| 85652 | <1% | 3,348 | $8K | |
| 82150 | <1% | 1,308 | $8K | |
| 83002 | <1% | 407 | $8K | |
| 86364 | <1% | 813 | $8K | |
| 82105 | <1% | 550 | $8K | |
| 80069 | <1% | 1,053 | $7K | |
| 85730 | <1% | 1,812 | $7K | |
| 86696 | <1% | 416 | $7K | |
| 84450 | <1% | 3,376 | $7K | |
| 82670 | <1% | 227 | $7K | |
| 84156 | <1% | 2,007 | $7K | |
| 86258 | <1% | 340 | $6K | |
| 86695 | <1% | 438 | $6K | |
| 82565 | <1% | 1,364 | $6K | |
| 86376 | <1% | 400 | $6K | |
| 84165 | <1% | 603 | $6K | |
| 82677 | <1% | 225 | $5K | |
| 86665 | <1% | 206 | $5K | |
| 82248 | <1% | 1,496 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 139 | $5K |
| 88342 | <1% | 169 | $5K | |
| 88304 | <1% | 290 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 133 | $5K |
| 86431 | <1% | 809 | $5K | |
| 87045 | <1% | 479 | $5K | |
| 83880 | <1% | 182 | $5K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 249 | $4K |
| 87272 | <1% | 312 | $4K | |
| 87269 | <1% | 312 | $4K | |
| 86336 | <1% | 224 | $3K | |
| 84550 | <1% | 844 | $3K | |
| 87015 | <1% | 507 | $3K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 166 | $3K |
| 86231 | <1% | 321 | $3K | |
| 82533 | <1% | 193 | $3K | |
| 85018 | <1% | 1,400 | $3K | |
| 82947 | <1% | 853 | $3K | |
| 80164 | <1% | 229 | $3K | |
| 85007 | <1% | 928 | $3K | |
| 86787 | <1% | 214 | $3K | |
| 82550 | <1% | 406 | $3K | |
| 84155 | <1% | 2,733 | $3K | |
| 81003 | <1% | 1,328 | $3K | |
| 82951 | <1% | 198 | $2K | |
| 87338 | <1% | 167 | $2K | |
| 82950 | <1% | 435 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 163 | $2K |
| 83525 | <1% | 276 | $2K | |
| 80051 | <1% | 438 | $2K | |
| 86664 | <1% | 120 | $2K | |
| 82977 | <1% | 350 | $2K | |
| 85014 | <1% | 968 | $2K | |
| 86225 | <1% | 144 | $2K | |
| 80177 | <1% | 146 | $2K | |
| 86706 | <1% | 228 | $2K | |
| 87329 | <1% | 175 | $2K | |
| 87158 | <1% | 305 | $2K | |
| 87328 | <1% | 149 | $2K | |
| 82310 | <1% | 419 | $2K | |
| 84520 | <1% | 527 | $2K | |
| 82274 | <1% | 118 | $2K | |
| 87486 | <1% | 35 | $1K | |
| 87581 | <1% | 35 | $1K | |
| 82247 | <1% | 2,232 | $1K | |
| 83630 | <1% | 66 | $1K | |
| 84100 | <1% | 310 | $1K | |
| 80178 | <1% | 182 | $1K | |
| 82785 | <1% | 75 | $1K | |
| 84144 | <1% | 48 | $1K | |
| 82040 | <1% | 2,117 | $952.48 | |
| 84075 | <1% | 2,111 | $896.45 | |
| 83010 | <1% | 62 | $829.33 | |
| 86039 | <1% | 65 | $785.29 | |
| 83021 | <1% | 53 | $772.40 | |
| 83883 | <1% | 59 | $751.78 | |
| 84703 | <1% | 83 | $749.04 | |
| 85004 | <1% | 107 | $723.46 | |
| 84132 | <1% | 185 | $719.07 | |
| 84402 | <1% | 33 | $716.69 | |
| 86800 | <1% | 49 | $711.78 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 49 | $707.54 |
| 86235 | <1% | 14 | $693.81 | |
| 82952 | <1% | 149 | $624.53 | |
| 83020 | <1% | 51 | $602.28 | |
| 80081 | <1% | 23 | $540.00 | |
| 81015 | <1% | 117 | $356.80 | |
| 82627 | <1% | 16 | $322.27 | |
| 88300 | <1% | 18 | $289.07 | |
| 86334 | <1% | 13 | $286.16 | |
| 86738 | <1% | 13 | $279.57 | |
| 84478 | <1% | 1,868 | $261.32 | |
| 86592 | <1% | 51 | $257.49 | |
| 84163 | <1% | 17 | $254.21 | |
| 83993 | <1% | 13 | $228.24 | |
| 84480 | <1% | 12 | $183.76 | |
| 82465 | <1% | 1,832 | $159.98 | |
| 84134 | <1% | 13 | $145.58 | |
| 86036 | <1% | 12 | $130.52 | |
| 82140 | <1% | 15 | $120.48 | |
| 85046 | <1% | 18 | $96.18 | |
| 86769 | <1% | 18 | $84.26 | |
| 83615 | <1% | 14 | $75.82 | |
| 83718 | <1% | 1,785 | $15.88 | |
| 0352U | 0% | 348 | $0.00 | |
| 87625 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSEN, KURT (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Catholic Health Initiatives-Iowa Corp | Des Moines, IA | $26.43M |
| Catholic Health Initiatives-Iowa Corp | West Des Moines, IA | $2.79M |
| Catholic Health Initiatives - Iowa Corp | West Des Moines, IA | $1.87M |
| Catholic Health Initiatives-Iowa Corp | Clive, IA | $594K |
| Catholic Health Initiatives-Iowa Corp | Ankeny, IA | $19K |
| Catholic Health Initiatives-Iowa Corp | Des Moines, IA | $3K |
| Catholic Health Initiatives-Iowa Corp | Ankeny, IA | $2K |
| Catholic Health Initiatives-Iowa Corp | Clive, IA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.